JCN Newswire Read More Lecanemab Receives Priority Review Status in Japan ruth 30 1 月 2 minutes TOKYO and CAMBRIDGE, Mass., Ja […]
JCN Newswire Read More Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency ruth 27 1 月 2 minutes TOKYO and CAMBRIDGE, Mass., Ja […]
JCN Newswire Read More Eisai Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer’s Disease in Japan ruth 16 1 月 3 minutes TOKYO and CAMBRIDGE, Mass., Ja […]
